recombinant canine  (Novus Biologicals)

Journal: Scientific Reports

Article Title: CXCL8 mediates macrophage migration in canine oral malignant melanoma

doi: 10.1038/s41598-025-22749-x

Figure Lengend Snippet: Relative number of RAW264.7 cells migrated by CMeC1 CM. The CM of CMeC1 wild-type or CXCL8 knockout cells were treated with dog CXCL8 recombinant protein (200 ng/ml). All data are presented as means ± SD of three independent experiments. ** P < 0.01; *** P < 0.001.

Article Snippet: Recombinant canine (NBP2-34908, Novus Biologicals) (same as the recombinant protein used in transwell migration assay), recombinant human CXCL8 protein (HZ-1318, Proteintech Group, Inc., Rosemont), or proten ectracted from CMeC1 underwent electrophoresis in 15% acrylamide gel.

Techniques: Knock-Out, Recombinant

Journal: Scientific Reports

Article Title: CXCL8 mediates macrophage migration in canine oral malignant melanoma

doi: 10.1038/s41598-025-22749-x

Figure Lengend Snippet: mRNA expression levels of chemokine in seven canine melanoma cell lines. a CCL5 , b CX3CL1 , c CSF-1 , d IL-34 , ( e ) CXCL8 , and ( f ) CCL2 . The relative expression level was normalized to the RPL32 gene . g Correlation between the number of migratory RAW264.7 and CXCL8 mRNA expression levels. h Production of CXCL8 in seven canine melanoma cell lines. i Correlation between the number of migratory RAW264.7 and CXCL8 secretion. All data are presented as means ± SD of three independent experiments.

Article Snippet: The recombinant canine CXCL8 protein (NBP2-34,908, Novus Biologicals, Centennial, CO, USA) was supplemented at a final concentration of 200 ng/mL into the CM.

Techniques: Expressing

Journal: Scientific Reports

Article Title: CXCL8 mediates macrophage migration in canine oral malignant melanoma

doi: 10.1038/s41598-025-22749-x

Figure Lengend Snippet: a , b Relative number of RAW264.7 cells migrated by CMeC1 wild-type CM or CMeC1 CXCL8 knockout CM. c Relative number of RAW264.7 cells migrated by CMeC1 CM. The CM of CMeC1 wild-type cells were treated with anti-dog CXCL8 (1 μg/ml) or mouse IgG isotype (1 μg/ml). All data are presented as means ± SD of three independent experiments. ** P < 0.01; *** P < 0.001.

Article Snippet: The recombinant canine CXCL8 protein (NBP2-34,908, Novus Biologicals, Centennial, CO, USA) was supplemented at a final concentration of 200 ng/mL into the CM.

Techniques: Knock-Out

Journal: Scientific Reports

Article Title: CXCL8 mediates macrophage migration in canine oral malignant melanoma

doi: 10.1038/s41598-025-22749-x

Figure Lengend Snippet: Relative number of RAW264.7 cells migrated by CMeC1 CM. The CM of CMeC1 wild-type or CXCL8 knockout cells were treated with dog CXCL8 recombinant protein (200 ng/ml). All data are presented as means ± SD of three independent experiments. ** P < 0.01; *** P < 0.001.

Article Snippet: The recombinant canine CXCL8 protein (NBP2-34,908, Novus Biologicals, Centennial, CO, USA) was supplemented at a final concentration of 200 ng/mL into the CM.

Techniques: Knock-Out, Recombinant

Journal: Scientific Reports

Article Title: CXCL8 mediates macrophage migration in canine oral malignant melanoma

doi: 10.1038/s41598-025-22749-x

Figure Lengend Snippet: Relative number of canine macrophage DH82 cells migrated by CMeC1 CM. The CM of CMeC1 wild-type or CXCL8 knockout were treated with anti-dog CXCL8 (1 μg/ml) or mouse IgG isotype (1 μg/ml). All data are presented as means ± SD of four independent experiments. ** P < 0.01; *** P < 0.001.

Article Snippet: The recombinant canine CXCL8 protein (NBP2-34,908, Novus Biologicals, Centennial, CO, USA) was supplemented at a final concentration of 200 ng/mL into the CM.

Techniques: Knock-Out